GSA Capital Partners LLP Acquires New Holdings in Insulet Corporation $PODD

Key Points

• GSA Capital Partners acquired 11,310 Insulet shares during the second quarter, valued at approximately $1.72 million. Several other institutional investors also initiated or increased positions.
• Insulet reported quarterly EPS of $1.66, exceeding the $1.47 estimate, while revenue rose 23.5% year over year to $801.7 million. The company’s Omnipod platform and recurring Pod revenue continue to support its long-term growth outlook.
• Analysts maintain a consensus “Hold” rating with an average price target of $195.40, although targets were recently reduced by several firms. Pending securities litigation alleging manufacturing and product-safety disclosure issues represents a near-term risk overhang.

GSA Capital Partners LLP bought a new stake in shares of Insulet Corporation (NASDAQ:PODD - Free Report) in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm bought 11,310 shares of the medical instruments supplier's stock, valued at approximately $1,722,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Larson Financial Group LLC increased its stake in shares of Insulet by 114.6% during the 4th quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier's stock worth $25,000 after purchasing an additional 47 shares in the last quarter. University of Texas Texas AM Investment Management Co. acquired a new position in shares of Insulet during the 4th quarter worth approximately $26,000. Elyxium Wealth LLC purchased a new stake in Insulet in the 4th quarter valued at approximately $28,000. DV Equities LLC acquired a new stake in Insulet during the 4th quarter valued at $28,000. Finally, MV Capital Management Inc. acquired a new stake in Insulet during the 4th quarter valued at $29,000.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. Robert W. Baird set a $175.00 price target on Insulet in a research report on Thursday, August 6th. Benchmark reduced their price objective on Insulet from $250.00 to $185.00 and set a "buy" rating on the stock in a research report on Thursday, August 6th. Evercore set a $180.00 price objective on Insulet in a research note on Monday, July 6th. Canaccord Genuity Group dropped their price objective on Insulet from $249.00 to $179.00 and set a "buy" rating for the company in a research report on Thursday, August 6th. Finally, Barclays cut their target price on shares of Insulet from $286.00 to $198.00 and set an "underweight" rating for the company in a research note on Thursday, May 7th. Fourteen research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus target price of $195.40.

Key Insulet News

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Insulet remains a long-term growth story: its Omnipod wearable insulin-delivery platform supports recurring revenue, while the company recently reported 23.5% year-over-year revenue growth, earnings above analyst expectations, and raised confidence in its full-year outlook. Why Insulet Is a Top Growth Stock for the Long-Term
• Neutral Sentiment: Multiple law firms are publicizing an August 31, 2026 deadline for investors to seek lead-plaintiff status in a pending federal securities class action. The announcements mainly solicit shareholder participation and do not establish liability or damages. Insulet Securities Fraud Lawsuit Deadline Alert
• Negative Sentiment: The litigation creates a significant near-term overhang. Complaints filed by investors allege that Insulet and certain executives made materially false or misleading statements concerning manufacturing controls and the safety and reliability of its insulin-delivery products. One notice specifically cites alleged defective cannula manufacturing that could have caused insulin under-delivery in millions of Omnipod devices. If substantiated, the claims could lead to financial costs, regulatory scrutiny, reputational damage, and weaker customer confidence. Insulet Securities Class Action Allegations

Insulet Stock Performance

NASDAQ PODD opened at $143.34 on Monday. The company's 50 day moving average price is $155.20 and its 200 day moving average price is $188.22. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.83 and a current ratio of 2.48. Insulet Corporation has a one year low of $126.40 and a one year high of $354.88. The firm has a market capitalization of $9.94 billion, a price-to-earnings ratio of 26.79, a PEG ratio of 1.13 and a beta of 1.10.

Insulet (NASDAQ:PODD - Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The medical instruments supplier reported $1.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.47 by $0.19. Insulet had a net margin of 12.29% and a return on equity of 29.29%. The firm had revenue of $801.70 million for the quarter, compared to the consensus estimate of $787.39 million. During the same quarter in the previous year, the firm posted $1.17 EPS. The firm's quarterly revenue was up 23.5% on a year-over-year basis. Insulet has set its FY 2026 guidance at 6.460- EPS. On average, sell-side analysts predict that Insulet Corporation will post 6.51 EPS for the current year.

Insider Buying and Selling

In other news, Director Timothy C. Stonesifer acquired 2,790 shares of the stock in a transaction that occurred on Wednesday, June 3rd. The stock was purchased at an average cost of $143.51 per share, with a total value of $400,392.90. Following the completion of the acquisition, the director directly owned 9,041 shares in the company, valued at $1,297,473.91. This represents a 44.63% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Company insiders own 0.36% of the company's stock.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company's core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet's products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company's product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.

Want to see what other hedge funds are holding PODD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insulet Corporation (NASDAQ:PODD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source